P16 Staining as Prognostic Biomarker in Serous Papillary Endometrial Cancer

Overview

P16 is a tumor suppressor protein implicated in serous papillary endometrial carcinoma. Evidence from previous trials indicates that it may be used as a diagnostic biomarker distinguishing this disease from endometrioid endometrial cancer. Additional evidence points to its prognostic value. The current study will evaluate p16 both as a diagnostic tool for serous papillary endometrial cancer and as a prognostic biomarker. following anonymization, histology blocks will be microtomed and stained for P16 and P53 proteins. Blocks from endometrioid endometrial cancer will be used as a control group.

Full Title of Study: “Expression of the P16 Protein in Serous Papillary Endometrial Cancer, and Its Clinical and Prognostic Significance”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: November 2010

Interventions

  • Other: no intervention

Arms, Groups and Cohorts

  • Serous papillary endometrial ca patients
    • 30 patients diagnosed with SP endometrial ca
  • Endometrioid endometrial ca
    • 32 patients diagnosed with Endometrioid endometrial ca

Clinical Trial Outcome Measures

Primary Measures

  • Overall survival
    • Time Frame: last followup (2-10 years)

Secondary Measures

  • progression free survival
    • Time Frame: Current follow up (2-10 years)
  • correlation of P16 stain with histological diagnosis
    • Time Frame: at last follow up (2-10 years)

Participating in This Clinical Trial

Inclusion Criteria

  • diagnosis of endometrial cancer – histology block exists in hospital's library Exclusion Criteria:

  • none

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Rambam Health Care Campus
  • Provider of Information About this Clinical Study
    • Dr. Itamar Netzer, Rambam Medical Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.